ArticleACS omega2026
Doxorubicin-Loaded Poly(Substituted Glycolide)-Based Nanoparticles for Long-Term Storage.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preventing agglomeration is crucial for polymeric nanoparticles (PNP) for drug-delivery applications. Suitable conditions for maintaining the size of doxorubicin (DOX)-loaded poly-(diisobutyl glycolide) (PDIBG) and poly-(diisopropyl glycolide) (PDIPG) nanoparticles (NP) during long-term storage were investigated in this study. After the synthesis of PDIBG and PDIPG homopolymers, DOX-loaded NPs were produced from these homopolymers by using a single-emulsion solvent evaporation method. The optimal formulations of DOX-loaded PDIBG and PDIPG-NPs were obtained with particle sizes of 253 ± 7 nm, PDIs of 0.06 ± 0.02, and an EE value of 58.3%, and particle sizes of 253 ± 7 nm, PDIs of 0.08 ± 0.04, and an EE value of 73.9%, respectively. To extend their shelf life, the developed NPs at three different concentrations (50, 70, and 90 mg/mL) were subjected to a comprehensive lyophilization process at two different freezing temperatures (-20 and -50 °C). As a result of the systematic lyophilization of sugar-containing and sugar-free formulations of DOX-loaded PDIBG and PDIPG-NPs under specific conditions, it was found that they could be stored at 4 and -20 °C for 2 months while maintaining their particle sizes and PDI values in the presence of glucose and sucrose (at 5 and 10% concentrations).
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.